[{"address1": "1560 Trapelo Road", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "781 786 8230", "fax": "781 786 8866", "website": "https://www.dyne-tx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 173, "companyOfficers": [{"maxAge": 1, "name": "Mr. John G. Cox M.B.A.", "age": 61, "title": "CEO, President & Director", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Romesh  Subramanian Ph.D.", "age": 59, "title": "Co-Founder & Advisor", "yearBorn": 1965, "fiscalYear": 2020, "totalPay": 565170, "exercisedValue": 0, "unexercisedValue": 284933}, {"maxAge": 1, "name": "Mr. Richard William Scalzo M.B.A.", "age": 38, "title": "Senior VP and Head of Finance & Administration", "yearBorn": 1986, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Oxana  Beskrovnaya Ph.D.", "age": 63, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2020, "totalPay": 631076, "exercisedValue": 0, "unexercisedValue": 1167727}, {"maxAge": 1, "name": "Mr. Daniel  Wilson", "age": 52, "title": "Senior VP & Head of Legal", "yearBorn": 1972, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lucia  Celona", "age": 58, "title": "Chief Human Resource Officer", "yearBorn": 1966, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Debra  Feldman", "age": 53, "title": "Chief Regulatory Affairs Officer", "yearBorn": 1971, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashish  Dugar M.B.A., Ph.D.", "title": "Chief Medical Affairs Officer", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Johanna  Friedl-Naderer", "age": 56, "title": "Chief Commercial Officer", "yearBorn": 1968, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Douglas  Kerr M.B.A., M.D., Ph.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1609372800, "maxAge": 86400, "priceHint": 2, "previousClose": 14.05, "open": 14.18, "dayLow": 13.76, "dayHigh": 14.5, "regularMarketPreviousClose": 14.05, "regularMarketOpen": 14.18, "regularMarketDayLow": 13.76, "regularMarketDayHigh": 14.5, "beta": 1.104, "forwardPE": -3.8784654, "volume": 950801, "regularMarketVolume": 950801, "averageVolume": 1704594, "averageVolume10days": 1678270, "averageDailyVolume10Day": 1678270, "bid": 13.86, "ask": 13.97, "bidSize": 100, "askSize": 100, "marketCap": 1415565056, "fiftyTwoWeekLow": 13.07, "fiftyTwoWeekHigh": 47.45, "fiftyDayAverage": 20.3632, "twoHundredDayAverage": 31.1145, "currency": "USD", "enterpriseValue": 716748480, "floatShares": 68464066, "sharesOutstanding": 101766000, "sharesShort": 9558513, "sharesShortPriorMonth": 10515884, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0939, "heldPercentInsiders": 0.008719999, "heldPercentInstitutions": 1.12291, "shortRatio": 3.28, "shortPercentOfFloat": 0.111499995, "impliedSharesOutstanding": 101766000, "bookValue": 6.934, "priceToBook": 2.006057, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -294513984, "trailingEps": -3.58, "forwardEps": -3.16, "enterpriseToEbitda": -2.291, "52WeekChange": -0.382146, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "DYN", "underlyingSymbol": "DYN", "shortName": "Dyne Therapeutics, Inc.", "longName": "Dyne Therapeutics, Inc.", "firstTradeDateEpochUtc": 1600349400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "bf98e34f-5989-3e23-b14d-e7c60952a6b7", "messageBoardId": "finmb_608699906", "gmtOffSetMilliseconds": -18000000, "currentPrice": 13.91, "targetHighPrice": 66.0, "targetLowPrice": 18.0, "targetMeanPrice": 49.5, "targetMedianPrice": 50.0, "recommendationKey": "none", "numberOfAnalystOpinions": 12, "totalCash": 723673984, "totalCashPerShare": 7.111, "ebitda": -312844000, "totalDebt": 24858000, "quickRatio": 16.728, "currentRatio": 17.022, "debtToEquity": 3.523, "returnOnAssets": -0.40354002, "returnOnEquity": -0.68684995, "freeCashflow": -144041248, "operatingCashflow": -243040000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]